🔗 Permalink

Inventor profile of:

Gale SMITH

City:

Gaithersburg, Maryland

Country:

United States

Published Applications:

Last publication date:

2026-04-16

Top Assignees for applications by Gale SMITH

The entities that hold a legal rights for patent applications filed by inventor SMITH Gale:

NOVAVAX, INC. 13 Gaithersburg, MD United States
NOVAVAX, INC. 2 Rockville, MD United States
Emory University 1 Atlanta, GA United States
THE UAB RESEARCH FOUNDATION 1 Birmingham, AL United States

Recent patent applications by SMITH Gale

Gale SMITH from Gaithersburg, US has applied for patents for these inventions. The list has both pending applications and granted patents:

#1 | 2026-04-16

US20260102481A1

Human necessities

CORONAVIRUS VACCINE FORMULATIONS

#2 | 2026-02-12

US20260041752A1

Human necessities

PNEUMOCOCCAL CONJUGATE VACCINES WITH SAPONIN-BASED ADJUVANTS

#3 | 2025-09-04

US20250276054A1

Human necessities

AVIAN INFLUENZA NANOPARTICLE IMMUNOGENIC COMPOSITIONS

#4 | 2025-04-03

US20250109187A1

Chemistry; metallurgy

ANTI-SARS-CoV-2 SPIKE (S) ANTIBODIES AND THEIR USE IN TREATING COVID-19

#5 | 2025-02-27

US20250066456A1

Chemistry; metallurgy

ANTI-SARS-CoV-2 SPIKE (S) ANTIBODIES AND THEIR USE IN TREATING COVID-19

#6 | 2025-01-23

US20250025549A1

Human necessities

CORONAVIRUS VACCINE FORMULATIONS

#7 | 2024-12-26

US20240423926A1

Human necessities

METHODS AND COMPOSITIONS FOR TREATING RESPIRATORY DISEASE

#8 | 2019-02-07

US20190038738A1

Human necessities

Functional influenza virus-like particles (VLPS)

#9 | 2017-12-14

US20170354729A1

Human necessities

VACCINE COMPOSITIONS CONTAINING MODIFIED ZIKA VIRUS ANTIGENS

#10 | 2017-11-09

US20170319682A1

Human necessities

RECOMBINANT NANOPARTICLE RSV F VACCINE FOR RESPIRATORY SYNCYTIAL VIRUS

#11 | 2017-09-07

US20170253861A1

Chemistry; metallurgy

Highly efficient influenza matrix (M1) proteins

#12 | 2017-09-07

US20170252427A1

Human necessities

Functional influenza virus-like particles (VLPS)

#13 | 2017-07-20

US20170202948A1

Human necessities

Vaccine compositions having improved stability and immunogenicity

#14 | 2016-07-21

US20160206729A1

Human necessities

Immunogenic middle east respiratory syndrome coronavirus (MERS-CoV) compositions and methods

#15 | 2016-01-14

US20160008456A1

Human necessities

Functional influenza virus-like particles (VLPS)

#16 | 2015-12-17

US20150359872A1

Human necessities

Modified RSV F proteins and methods of their use

#17 | 2015-11-26

US20150335730A1

Human necessities

RECOMBINANT NANOPARTICLE RSV F VACCINE FOR RESPIRATORY SYNCYTIAL VIRUS

#18 | 2015-10-29

US20150307849A1

Chemistry; metallurgy

Highly efficient influenza matrix (M1) proteins

#19 | 2015-10-29

US20150306207A1

Human necessities

RECOMBINANT NANOPARTICLE RSV F VACCINE FOR RESPIRATORY SYNCYTIAL VIRUS

#20 | 2015-09-24

US20150266930A1

Chemistry; metallurgy

Modified RSV F proteins and methods of their use

#21 | 2015-09-24

US20150265698A1

Human necessities

Modified RSV F proteins and methods of their use

#22 | 2014-10-02

US20140294879A1

Chemistry; metallurgy

Modified RSV F proteins and methods of their use

#23 | 2013-02-14

US20130039938A1

Chemistry; metallurgy

Highly efficient influenza matrix (M1) proteins

#24 | 2010-09-30

US20100247574A1

Chemistry; metallurgy

CHIMERIC NEWCASTLE DISEASE VIRUS VLPs

#25 | 2010-09-23

US20100239617A1

Human necessities

Modified RSV F proteins and methods of their use

#26 | 2010-08-05

US20100196419A1

Chemistry; metallurgy

Virus-like particles comprising chimeric human immunodeficiency virus (HIV)/mouse mammary tumor virus (MMTV) envelopes

InventorID:

89270 ⎘